The evolving role of the multiple sclerosis nurse: an international perspective.
A greater understanding of the pathogenesis of multiple sclerosis (MS) and the need for treatments with increased efficacy, safety, and tolerability have led to the ongoing development of new treatments. The evolution of treatments for MS is expected to have a dramatic impact on the entire health-care team, especially MS nurses, who build strong collaborative partnerships with their patients. MS nurses help patients better understand their disease and treatment options, facilitate the initiation and management of treatment, and encourage adherence. With new oral therapies entering the market, the potential for increased efficacy, tolerability, adherence, and convenience for patients is evident. However, the resulting change in the treatment paradigm means that the skill set required of an MS nurse will inevitably expand. There will be a growing need for professional training and development to ensure that nurses are familiar with the wider range of treatments and their specific modes of action, dosing schedules, and benefit/risk profiles. In addition, the MS nurse's role will expand to include management of the complex monitoring needs specific to each therapy. This article explores how the role of the MS nurse is evolving with the development of new MS therapies, including novel oral therapies.
Institute for Immunology & Allergy Research, Westmead Millennium Institute, Westmead, Sydney, Australia (TB); Carmel Medical Centre, Haifa, Israel (SD); London Health Sciences Centre, Multiple Sclerosis Clinic, London, Ontario, Canada (LM); and Fort Lauderdale MS Center, Pompano Beach, FL, USA (JS).
Therese
T
Burke
Institute for Immunology & Allergy Research, Westmead Millennium Institute, Westmead, Sydney, Australia (TB); Carmel Medical Centre, Haifa, Israel (SD); London Health Sciences Centre, Multiple Sclerosis Clinic, London, Ontario, Canada (LM); and Fort Lauderdale MS Center, Pompano Beach, FL, USA (JS).
Sara
S
Dishon
Institute for Immunology & Allergy Research, Westmead Millennium Institute, Westmead, Sydney, Australia (TB); Carmel Medical Centre, Haifa, Israel (SD); London Health Sciences Centre, Multiple Sclerosis Clinic, London, Ontario, Canada (LM); and Fort Lauderdale MS Center, Pompano Beach, FL, USA (JS).
Lynn
L
McEwan
Institute for Immunology & Allergy Research, Westmead Millennium Institute, Westmead, Sydney, Australia (TB); Carmel Medical Centre, Haifa, Israel (SD); London Health Sciences Centre, Multiple Sclerosis Clinic, London, Ontario, Canada (LM); and Fort Lauderdale MS Center, Pompano Beach, FL, USA (JS).
Jennifer
J
Smrtka